111 related articles for article (PubMed ID: 26147895)
21. Treatment of Gaucher's disease with OGT 918.
Kranda M
Lancet; 2000 Aug; 356(9230):677. PubMed ID: 10968455
[No Abstract] [Full Text] [Related]
22. Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy.
Kim YM; Shin DH; Park SB; Cheon CK; Yoo HW
BMC Med Genet; 2017 May; 18(1):55. PubMed ID: 28506293
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
[TBL] [Abstract][Full Text] [Related]
24. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
25. A novel method for preparing Eligulstat through chiral resolution.
Du J; Chu W; Zhang M; Ma C; Feng W
Bioorg Med Chem Lett; 2020 Aug; 30(16):127209. PubMed ID: 32461019
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience.
Duminuco A; Fazio M; Grasso S; Gullo L; Riccobene C; Calafiore V; Markovic U; Di Raimondo F; Giuffrida G
Clin Ther; 2023 Nov; 45(11):1105-1110. PubMed ID: 37722956
[TBL] [Abstract][Full Text] [Related]
27. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
28. [New oral therapy option].
Grzegorek K
MMW Fortschr Med; 2015 Jul; 157(13):77. PubMed ID: 26206047
[No Abstract] [Full Text] [Related]
29. Modeling non-clinical and clinical drug tests in Gaucher disease.
Phelix CF; Bourdon AK; Villareal G; LeBaron RG
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():1434-1438. PubMed ID: 28268595
[TBL] [Abstract][Full Text] [Related]
30. Long-term eliglustat treatment of Gaucher patients over up to 10 years in Vienna.
Stulnig TM
Wien Klin Wochenschr; 2022 Jun; 134(11-12):471-477. PubMed ID: 35412052
[TBL] [Abstract][Full Text] [Related]
31. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
Trapero A; Llebaria A
Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
[No Abstract] [Full Text] [Related]
32. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
33. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
Wilson MW; Shu L; Hinkovska-Galcheva V; Jin Y; Rajeswaran W; Abe A; Zhao T; Luo R; Wang L; Wen B; Liou B; Fannin V; Sun D; Sun Y; Shayman JA; Larsen SD
ACS Chem Neurosci; 2020 Oct; 11(20):3464-3473. PubMed ID: 33035424
[TBL] [Abstract][Full Text] [Related]
34. [Drug for Gaucher disease also works as sperm inhibitor. Is the "pill" for the man on its way?].
Cooper T
MMW Fortschr Med; 2003 Feb; 145(7):22. PubMed ID: 12652820
[No Abstract] [Full Text] [Related]
35. A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.
Abrams R; Kaddi CD; Tao M; Leiser RJ; Simoni G; Reali F; Tolsma J; Jasper P; van Rijn Z; Li J; Niesner B; Barrett JS; Marchetti L; Peterschmitt MJ; Azer K; Neves-Zaph S
CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):374-383. PubMed ID: 32558397
[TBL] [Abstract][Full Text] [Related]
36. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective.
Shayman JA
Am J Physiol Renal Physiol; 2015 Dec; 309(12):F996-9. PubMed ID: 26447223
[TBL] [Abstract][Full Text] [Related]
37. Genotype-based treatment approved for type 1 Gaucher disease.
Thompson CA
Am J Health Syst Pharm; 2014 Oct; 71(19):1606. PubMed ID: 25225441
[No Abstract] [Full Text] [Related]
38. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
39. Molecule of the month. Talabostat.
Drug News Perspect; 2006 Jun; 19(5):299. PubMed ID: 16941051
[No Abstract] [Full Text] [Related]
40. Copy number variations' effect on drug response still overlooked.
Willyard C
Nat Med; 2015 Mar; 21(3):206. PubMed ID: 25742449
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
